Nuvo Pharmaceuticals (NRIFF) Stock Price, News & Analysis

Company Overview

Nuvo Pharmaceuticals Inc. was a Canadian specialty pharmaceutical company focused on developing, commercializing and licensing therapies for pain, inflammation and related health conditions. The company’s activities included the acquisition, development and commercialization of branded and specialty pharmaceutical products for prescription and consumer healthcare markets.

Nuvo’s product portfolio included PENNSAID, a topical diclofenac treatment for osteoarthritis-related pain, as well as Resultz, an over-the-counter treatment for head lice. The company also pursued additional pharmaceutical and healthcare products through internal research, licensing arrangements and strategic acquisitions.

Based in Canada, Nuvo served markets in Canada, the United States and other international jurisdictions through direct commercial activities and partnerships. In 2021, Searchlight Pharma Inc. completed the acquisition of Nuvo Pharmaceuticals, after which Nuvo ceased operating as an independent publicly traded company.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 3,000 shs
• Average Volume: 7,337 shs
• Market Capitalization: $8.52 million
• P/E Ratio: 18.69
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:NRIFF
• CIK: N/A
• Web: www.nuvopharmaceuticals.com
• Phone: (905) 673-6980
• Fax: N/A
• Employees: 99
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.04
• Trailing P/E Ratio: 18.69
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.53 million
• Net Margins: -2.81%
• Pretax Margin: N/A
• Return on Equity: 8.02%
• Return on Assets: 1.11%

Debt

• Debt-to-Equity Ratio: 5.27
• Current Ratio: 2.67
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $52.41 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.82
• Book Value: $1.59 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,400,000
• Free Float: N/A
• Market Cap: $8.52 million
• Optionable: Not Optionable
• Beta: 1.57